

Recommendations for Government

to facilitate Smooth
Business Operations of
Pharmaceutical Companies
under the 'New Normal'



The Pharmaceutical and Healthcare Association of the Philippines (PHAP) and its member companies are committed to partner with the Philippine Government in ensuring that all Filipino patients have continued access to medicines, vaccines and medical devices in this time of COVID-19 pandemic.

With the increasing challenges posed by this pandemic, PHAP members have stepped-up their efforts:



to fast track the development of safe and effective COVID-19 treatments and vaccines



to implement measures for uninterrupted supply of medicines for both COVID-19 and other conditions



to launch a campaign to protect our health workers and generate funds for their medical needs.

Research-based companies have stepped up efforts to develop diagnostics, vaccines and treatments in response to COVID-19

Checking existing drug and vaccine portfolios

 Our scientists are searching for potentially useful assets that could help with the development of new or repurposed treatments or vaccines to fight against the novel coronavirus.

These include diagnostics and biomarkers, approved therapies or compounds in development.

133

Potential treatments under study

82

Candidate vaccines under pre-clinical evaluation

7



Collaborating to fast track the development of treatments and vaccines

 We are collaborating with governments, global health and research organisations, and pharmaceutical laboratories to share knowledge, libraries and technologies. More recently, we co-launched a landmark global collaboration called 'Access to COVID-19 Tools (ACT) Accelerator'

CEPI

New vaccines for a safer world

**im!**

innovative medicines initiative

 **BILL & MELINDA GATES foundation**

 **NIH**
National Institutes of Health

Accelerating manufacturing capabilities

 We are leveraging our manufacturing technologies to allow a rapid upscale of production once a medicine or vaccine candidate is identified to meet the needs of most affected populations.

**Abbott**

 **astellas**
Leading Light for Life

**AstraZeneca**

**BAYER**

**Boehringer Ingelheim**

**Eisai**

**gsk**
GlaxoSmithKline

**Johnson & Johnson**

**MERCK**

**MSD**


**NOVARTIS**

**Pfizer**

**Roche**

**SANOFI**

**Takeda**

**ZUELLIG PHARMA**

PHAP-members have implemented measures for uninterrupted supply of medicines for COVID and other life-threatening conditions

Ensuring manufacturing capacity are at optimal levels

Keeping plants open to maintain steady supply of medicines

Managing inventories, redirecting supplies towards the Philippines



Distributing medicines across checkpoints implemented through varying local ordinances.

Implementing new logistical arrangements, chartering flights

Collectively, these have substantially increased costs and expenses taken and absorbed by companies

1

WE REQUEST THE GOVERNMENT TO IMPLEMENT MEASURES TO MITIGATE SUPPLY CHAIN CHALLENGES DURING THE PANDEMIC.




Unhampered transport and distribution of medicines under Enhanced Community Quarantine



Availability of government forecast on medicine supply needs in the country



Establishment of sound regulatory guidelines facilitating access to medicines and vaccines



Management of retail and maximum consumer purchases



Strong communication and collaboration with the private sector

1

WE REQUEST THE GOVERNMENT TO IMPLEMENT MEASURES TO MITIGATE SUPPLY CHAIN CHALLENGES DURING THE PANDEMIC.



Unhampered transport and distribution of medicines under Enhanced Community Quarantine

- Single guideline for all LGUs
- Special lanes for pickup, delivery, including personnel assigned to these tasks
- Support for the continued movement of essential supplies in cases of port closures.
- Expedited Customs clearance especially for temperature sensitive products



Availability of government forecast on medicine supply needs in the country

- Forecasts on which medicines and how many are needed in the country for the duration of the pandemic, for adequate production planning and inventory management.

1

WE REQUEST THE GOVERNMENT TO IMPLEMENT MEASURES TO MITIGATE SUPPLY CHAIN CHALLENGES DURING THE PANDEMIC.



Establishment of sound regulatory guidelines facilitating access to medicines and vaccines

- Joint guidelines for the entry, use, dispensing, and monitoring of experimental therapies and diagnostics
- Special certification schemes, accelerated approval/compassionate entry for potential novel treatments
- Exemptions from country specific labeling requirements to address supply/services restrictions



**Coronavirus
Treatment
Acceleration
Program (CTAP)**


EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH
Guidance for medicine developers and
companies on COVID-19 


Australian Government
Department of Health
Therapeutic Goods Administration

**Clinical Trial
Notification**
**Special Access
Scheme**

1

WE REQUEST THE GOVERNMENT TO IMPLEMENT MEASURES TO MITIGATE SUPPLY CHAIN CHALLENGES DURING THE PANDEMIC.



Management of retail and maximum consumer purchases

- Encourage patients not to overstock
- Implementation and monitoring of maximum purchase policy
- Exemptions from country specific labeling requirements to address supply/services restrictions



Strong communication and collaboration with the private sector

- Continuous dialogue and collaboration with research-based pharma companies
- Supply Security TWG
- Collaborative activities – webinars, hackathons

Recommendations for Government

to facilitate Smooth Business Operations of Pharmaceutical Companies under the 'New Normal'

- 1 WE REQUEST THE GOVERNMENT TO IMPLEMENT MEASURES TO MITIGATE SUPPLY CHAIN CHALLENGES DURING THE PANDEMIC.
- 2 WE APPEAL FOR THE GOVERNMENT TO EXPLORE SUSTAINABLE APPROACHES TOWARDS IMPROVING ACCESS TO MEDICINES, AND IMPOLE TO RESCIND THE IMPLEMENTATION OF PRICE CUTS THAT WILL FURTHER AGGRAVATE THE EFFECTS OF THE CRISIS AND HAMPER INDUSTRY'S RECOVERY.
- 3 WE SEEK AN ENABLING ENVIRONMENT THAT IS VITAL FOR RESEARCH-DRIVEN PHARMACEUTICAL COMPANIES TO THRIVE IN THE COUNTRY, THUS EQUIPPING THE PHILIPPINES AGAINST CURRENT AND EMERGING PUBLIC HEALTH THREATS.

WE APPEAL FOR THE GOVERNMENT TO EXPLORE SUSTAINABLE APPROACHES TOWARDS IMPROVING ACCESS TO MEDICINES, AND IMPOSE TO RESCIND THE IMPLEMENTATION OF PRICE CUTS THAT WILL FURTHER AGGRAVATE THE EFFECTS OF THE CRISIS AND HAMPER INDUSTRY'S RECOVERY.

Instead of mandatory price cuts, we ask the government to consider more sustainable approaches to improving access to medicines, viable for an industry that has contributed and closely worked with the government in this pandemic.

We advocate for:



WE APPEAL FOR THE GOVERNMENT TO EXPLORE SUSTAINABLE APPROACHES TOWARDS IMPROVING ACCESS TO MEDICINES, AND IMPOSE TO RESCIND THE IMPLEMENTATION OF PRICE CUTS THAT WILL FURTHER AGGRAVATE THE EFFECTS OF THE CRISIS AND HAMPER INDUSTRY'S RECOVERY.

Better prices through pooled procurement

P38,272

Hospital
Procurement



P13,000

DOH
Procurement

Pooled procurement is a timely support that the government can provide to the Filipino people, especially for those whose finances have already been affected by COVID 19

WE SEEK AN ENABLING ENVIRONMENT THAT IS VITAL FOR RESEARCH-DRIVEN PHARMACEUTICAL COMPANIES TO THRIVE IN THE COUNTRY, THUS EQUIPPING THE PHILIPPINES AGAINST CURRENT AND EMERGING PUBLIC HEALTH THREATS.

A BUSINESS ENVIRONMENT CONDUCIVE TO INNOVATION



Building capabilities for advanced science, technology, and innovation.



Formulating policies that enable, support and incentivize innovation.



Forging public-private partnerships on pharmaceutical security and improving access to medicines





Thank you!



Abbott



**Calmoseptine
Ointment**



Johnson & Johnson



**VIZCARRA
PHARMACEUTICAL**

ZUELLIG PHARMA

